SCHEMBL6792301

SCHEMBL6792301

O=C(Nc1ccc(NCCc2ccccn2)cc1)c1ccccc1-c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
NPC1 O15118 2/20 0.55
RAB9A P51151 2/20 0.55
ALDH1A1 P00352 5/20 0.53
MAPT P10636 4/20 0.53
HTT P42858 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
RXFP1 Q9HBX9 2/20 0.53
KDR P35968 2/20 0.46
LMNA P02545 3/20 0.46
HDAC6 Q9UBN7 1/20 0.46
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
HPGD P15428 1/20 0.45
CYP2C19 P33261 1/20 0.45
KDM4E B2RXH2 1/20 0.45
SMO Q99835 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7080428 0.89 MEN1 (0.51) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL6791511 0.88 HTT (0.57) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL6796673 0.88 HTT (0.59) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL6789227 0.87 LMNA (0.50) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL6792583 0.87 KMT2A (0.56) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL6793890 0.86 RAB9A (0.54) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL6794915 0.86 LMNA (0.49) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL6787263 0.86 HTT (0.49) MEN1KMT2ANPC1RAB9AALDH1A1
SCHEMBL6793707 0.86 CNR1 (0.58) NPC1RAB9AALDH1A1HTTSMN1; SMN2
SCHEMBL6788981 0.86 HTT (0.49) MEN1KMT2ANPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058903-A1 Benzamide compounds as apo b secretion inhibitors APOB, APOL1, SCARB1 MEN1 2426/4885KMT2A 2457/4885NPC1 64/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.